title: [Therapeutic options in hormone refractory prostate carcinoma].
authors.affiliation: Klinik und Poliklinik für Urologie, Universitätsklinik Hamburg-Eppendorf.
authors.forename: M
authors.initials: M
authors.lastname: Graefen
authors.forename: P
authors.initials: P
authors.lastname: Hammerer
authors.forename: A
authors.initials: A
authors.lastname: Haese
authors.forename: H
authors.initials: H
authors.lastname: Huland
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal
vernacular_title: Therapieoptionen des hormonrefraktären Prostatakarzinoms.